

Updates in Lung Cancer Treatment

Eziafa I. Oduah MD, PhD, MPH Assistant Professor of Medicine Division of Medical Oncology Duke University, School of Medicine Duke Cancer Institute



Disclosures

- No conflicts of interest related to this talk
- Research Funding: Bristol Myers Squib Foundation
- Advisory Board: Genentech

Outline



Introduction

Updates in Small Cell Lung Cancer (SCLC)

- Early Stage ADRIATIC
- Metastatic DeLLphi-301

Updates in Non-Small Cell Lung Cancer (NSCLC)

- Early stage
- ALK + : ALINA
- EGFR+: LAURA TRIAL
- Metastatic
- ALK +: CROWN
- KRAS+: KRYSTAL 12, SUNRAY -01
- HER2+: Zongertinib
- EGFR IV vs SC Amivantamab

Summary

Introduction



Prostat Lung & bronch Colon & rectur Urinary bladd Melanoma of the ski Kidney & renal pelv Non-Hodgkin lymphom Oral cavity & pharym Leukemi Pancrea All Site


Estimated New Cases

			Males	Female	S		
Prostate	268,490	27%			Breast	287,850	31%
Lung & bronchus	117,910	12%			Lung & bronchus	118,830	13%
Colon & rectum	80,690	8%		X	Colon & rectum	70,340	8%
Urinary bladder	61,700	6%			Uterine corpus	65,950	7%
Melanoma of the skin	57,180	6%			Melanoma of the skin	42,600	5%
Kidney & renal pelvis	50,290	5%			Non-Hodgkin lymphoma	36,350	4%
Non-Hodgkin lymphoma	44,120	4%			Thyroid	31,940	3%
Oral cavity & pharynx	38,700	4%			Pancreas	29,240	3%
Leukemia	35,810	4%			Kidney & renal pelvis	28,710	3%
Pancreas	32,970	3%			Leukemia	24,840	3%
All Sites	983,160	100%			All Sites	934,870	100%

			Males	Female	S		
Lung & bronchus	68,820	21%			Lung & bronchus	61,360	21%
Prostate	34,500	11%			Breast	43,250	15%
Colon & rectum	28,400	9%		2	Colon & rectum	24,180	8%
Pancreas	25,970	8%			Pancreas	23,860	8%
Liver & intrahepatic bile duct	20,420	6%			Ovary	12,810	4%
Leukemia	14,020	4%			Uterine corpus	12,550	4%
Esophagus	13,250	4%			Liver & intrahepatic bile duct	10,100	4%
Urinary bladder	12,120	4%			Leukemia	9,980	3%
Non-Hodgkin lymphoma	11,700	4%			Non-Hodgkin lymphoma	8,550	3%
Brain & other nervous system	10,710	3%			Brain & other nervous system	7,570	3%
All Sites	322,090	100%			All Sites	287,270	100%


Seigel et al, Cancer statistics 2022

Considerations for the treatment of lung cancer




Seigel et al, Cancer statistics 2022

Therapeutic landscape of lung cancer



Landscape of systemic therapies for lung lancer





DeLLphi-301: Tarlatamab phase 2 trial in small cell lung cancer (SCLC)—Efficacy and safety analyzed by presence of brain metastases

Anne-Marie C. Dingemans,¹ Myung-Ju Ahn,² Fiona Blackhall,³ Martin Reck,⁴ Horst-Dieter Hummel,⁵ Suresh S. Ramalingam,⁶ Melissa L. Johnson,⁷ Hiroaki Akamatsu,⁸ Jürgen Wolf,⁹ Jacob Sands,¹⁰ Taofeek K.Owonikoko,¹¹ Hossein Borghaei,¹² Sujoy Mukherjee,¹³ Shuang Huang,¹³ Pablo Martinez,¹³ Luis Paz-Ares¹⁴


¹Department of Pulmonary Medicine, Erasmus MC Cancer Institute, Rotterdam, Netherlands; ²Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; ³The Christie NHS Foundation Trust, Manchester, UK; ⁴Interdisciplinary Study Center, Translational Oncology/Early Clinical Trial Unit (ECTU), Comprehensive Cancer Center Mainfranken, Würzburg, Germany; ⁵Translational Oncology/Early Clinical Trial Unit, Universitätsklinikum Würzburg, Comprehensive Cancer Center Mainfranken, Würzburg, Germany; ⁵Translational Oncology/Early Clinical Trial Unit, Universitätsklinikum Würzburg, Comprehensive Cancer Center Mainfranken, Würzburg, Germany; ⁶Winship Cancer Institute of Emory University, Atlanta, GA, USA; ⁷Sarah Cannon Research Institute at Tennessee Oncology, Nashville, TN, USA; ⁶Wakayama Medical University Hospital, Wakayama, Japan; ⁹Department I Internal Medicine - Center for Integrated Oncology, Universitätsklinikum Köln (AöR), Cologne, Germany; ¹⁰Dana-Farber Cancer Cancer, Mervard Medical School, Boston, MA, USA; ¹¹Division of Hematology-Oncology, University of Maryland, Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA; ¹²Fox Chase Cancer Center, Philadelphia, PA, USA; ¹³Amgen Inc., Thousand Oaks, CA, USA; ¹⁴Hospital Universitatio 12 de Octubre, CNIC-H120 Lung Cancer Unit, Complutense University and Ciberone, Madrid, Spain.



PRESENTED BY: Anne-Marie C. Dingemans, MD, PhD

Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org.













Phase 2 DeLLphi-301 Study Design



Subgroup Analysis: Efficacy by BICR and safety, by presence or absence of baseline brain metastases **Post-hoc Analysis:** Intracranial activity





Ahn et al, N Engl J Med 2023;389:2063-2075



Efficacy Summary

	Tarlatamab 10 mg Q2W* (n = 100) [†]					
Baseline brain metastases:	Yes (n = 23)	No (n = 77)				
ORR, % (95% CI)	52 (31–73)	38 (27–49)				
Median DOR, months (range)	NE (3–12+)	NE (2–12+)				
DOR probability at 12 months, KM estimate, % (95% CI)	55 (22–78)	50 (29–68)				
Median PFS, months (95% CI)	6.7 (3–NE)	4.0 (3–6)				
Median OS [‡] , months (95% CI)	14.3 (14–NE)	NE (9–NE)				

Tarlatamab demonstrated durable response with promising survival regardless of the presence of treated, stable brain metastases at baseline

Data cutoff, June 27, 2023. Median follow-up: 10.6 months. *Given as 1 mg on Day 1, followed by 10 mg on Days 8, 15, and Q2W thereafter. For 100 mg data, scan QR code or see https://meetings.asco.org/abstracts-presentations/232383. [†]The intention-to-treat analysis set consists of all patients who were randomized and enrolled according to assigned treatment dose levels. [‡]OS data yet to mature. CI, confidence interval; DOR, duration of response; KM, Kaplan-Meier; NE, not estimable; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; Q2W, every 2 weeks.











NCCN National Comprehensive Cancer Network®

NCCN Guidelines Version 3.2024 Small Cell Lung Cancer

Cons	SCLC SUBSEQUENT SYSTEMIC THERAPY (PS 0–2) ^{f,} ider dose reduction or growth factor support for patients with PS 2.
	CHEMOTHERAPY-FREE INTERVAL (CTFI) >6 MONTHS
Preferred Regimens	
Clinical trial enrollment	
• Re-treatment with platinum	based doublet ^{g,34,35,37-39}
Other Recommended Regime • Lurbinectedin ^{17,36}	
• Topotecan oral (PO) or intra	venous (IV) ^{14-16,28}
• Irinotecan ^{h,21,28}	
• Tarlatamab-dlle ^{i,47}	
	CTFI ≤6 MONTHS
Preferred Regimens • Clinical trial enrollment • Lurbinectedin ^{17,36} • Topotecan oral (PO) or intra • Irinotecan ^{h,21,28} • Tarlatamab-dlle ^{i,47} • Re-treatment with platinum	venous (IV) ^{14-16,28,37} based doublet may be considered for CTFI 3–6 months ^{g,37,38,39}
Other Recommended Regime • Nivolumab or pembrolizuma • Paclitaxel ^{18,19} • Temozolomide ^{22,23} • Cyclophosphamide/doxorul • Docetaxel ²⁰ • Gemcitabine ^{26,27,40} • Oral etoposide ^{24,25}	ab (if not previously treated with an ICI) ^{b, 29,30,31,32,33}





ADRIATIC: durvalumab as consolidation treatment for patients with limited-stage small-cell lung cancer (LS-SCLC)

<u>David R. Spigel</u>, Ying Cheng, Byoung Chul Cho, Konstantin Laktionov, Jian Fang, Yuanbin Chen, Yoshitaka Zenke, Ki Hyeong Lee, Qiming Wang, Alejandro Navarro, Reyes Bernabe, Eva Buchmeier, John Wen-Cheng Chang, Isamu Okamoto, Sema Sezgin Goksu, Andrzej Badzio, Bethany Gill, Hema Gowda, Haiyi Jiang, Suresh Senan








ADRIATIC study design

Phase 3, randomized, double-blind, placebo-controlled, multicenter, international study (NCT03703297)



*cCRT and PCI treatment, if received per local standard of care, must have been completed within 1–42 days prior to randomization. [†]If disease control was achieved and no additional benefit was expected with an additional cycle of chemotherapy, in the opinion of the investigator. [‡]The first 600 patients were randomized in a 1:1:1 ratio to the 3 treatment arms; subsequent patients were randomized 1:1 to either durvalumab or placebo.



PRESENTED BY: Dr David R. Spigel

Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org.


BICR, blinded independent central review; BID, twice daily; CT, chemotherapy; D, durvalumab; PCI, prophylactic cranial irradiation; PS, performance status; Q4W, every 4 weeks; QD, once daily; RECIST, Response Evaluation Criteria in Solid Tumors; rg. RT, radiotherapy; T, tremelimumab; WHO, World Health Organization.





Overall survival (dual primary endpoint)

• Median duration of follow up in censored patients: 37.2 months (range 0.1-60.9)



OS was analyzed using a stratified log-rank test adjusted for receipt of PCI (yes vs no). The significance level for testing OS at this interim analysis was 0.01679 (2-sided) at the overall 4.5% level, allowing for strong alpha control across interim and final analysis timepoints.





Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org

CI, confidence interval; mOS, median OS; NE, not estimable.

AMERICAN SOCIETY OF



OS subgroup analysis

Events/Patients n/N								
		Durvalumab	Placebo		HR (95% CI)			
All patients		115/264	146/266	[●1]	0.73 (0.57-0.93)			
Age	<65 years ≥65 years	69/160 46/104	83/162 63/104		0.76 (0.55–1.04) 0.70 (0.48–1.02)			
Sex	Male Female	79/178 36/86	108/188 38/78		0.70 (0.52–0.93) 0.83 (0.52–1.31)			
Race	White Asian	60/130 53/131	77/137 64/121		0.75 (0.53–1.05) 0.72 (0.50–1.04)			
WHO performance status	0 1	48/133 67/131	74/131 72/135		0.55 (0.38–0.79) 0.94 (0.67–1.31)			
AJCC disease stage at diagnosis	1/11 111	11/33 104/231	12/34 134/232		H 0.92 (0.40–2.11) 0.71 (0.55–0.91)			
Time from end of cCRT* to randomization	<14 days ≥14 days to <28 days ≥28 days	14/32 37/79 64/153	24/32 51/80 71/154		0.47 (0.24–0.91) 0.59 (0.38–0.90) 0.90 (0.64–1.27)			
Prior chemotherapy regimen	Carboplatin-etoposide Cisplatin-etoposide	31/ 91 84/173	46/88 100/178		0.56 (0.35–0.89) 0.82 (0.61–1.10)			
Prior radiation schedule	Once daily Twice daily	92/195 23/69	107/187 39/79		0.72 (0.55–0.95) 0.68 (0.40–1.14)			
Best response to prior cCRT	Complete response Partial response Stable disease	12/31 88/191 15/42	15/34 116/200 15/32		0.90 (0.41–1.92) 0.76 (0.57–1.00) 0.54 (0.25–1.13)			
Prior PCI	Yes No	53/142 62/122	67/143 79/123		0.75 (0.52–1.07) 0.71 (0.51–0.99)			
				0.25 0.5 1 2	2			

*End of chemotherapy or radiotherapy, whichever was latest.

#ASCO24

Intention-to-treat analysis stratified, subgroup analyses unstratified. Not all prespecified subgroups are included in the plot. Size of circle is proportional to number of events across both arms.

Favors durvalumab Favors placebo

ASCO AMERICAN SOCIETY OF CLINICAL ONCOLOGY KNOWLEDGE CONQUERS CANCER



Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org

Summary: Updates in SCLC



✓ Tarlatamab is FDA approved and in NCCN guidelines for extensive stage SCLC in the 2L.

 Consolidation Durvalumab should be the new SOC for limited stage SCLC patients after concurrent chemoRT.

✓ Molecular profiling and stratification of SCLC is promising.



The NEW ENGLAND JOURNAL of MEDICINE

SPECIALTIES V TOPICS V MULTIMEDIA V CURRENT ISSUE V LEARNING/CME V AUTHOR CENTER PUBLICATIONS V

ORIGINAL ARTICLE

f Ӂ in ∣


Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer

Authors: Yi-Long Wu, M.D. ^(D), Rafal Dziadziuszko, M.D., Ph.D., Jin Seok Ahn, M.D., Ph.D., Fabrice Barlesi, M.D., Ph.D., Makoto Nishio, M.D., Ph.D., Dae Ho Lee, M.D., Ph.D., Jong-Seok Lee, M.D., Ph.D., ⁺¹⁵, for the ALINA Investigators^{*} Author Info & Affiliations

Published April 10, 2024 | N Engl J Med 2024;390:1265-1276 | DOI: 10.1056/NEJMoa2310532 | VOL. 390 NO. 14



ALINA study design*



Primary endpoint

- DFS per investigator,[‡] tested hierarchically:
 - Stage II–IIIA \rightarrow ITT (Stage IB–IIIA)

Other endpoints

- CNS disease-free survival
- OS
- Safety

Disease assessments (including brain MRI)[§] were conducted: at baseline, every 12 weeks for year 1–2, every 24 weeks for year 3–5, then annually



Data cut-off: 26 June 2023; CNS, central nervous system; DFS, disease-free survival; ITT, intention to treat *Superiority trial; †Cisplatin + pemetrexed, cisplatin + vinorelbine or cisplatin + gemcitabine; cisplatin could be switched to carboplatin in case of intolerability; ‡DFS defined as the time from randomisation to the first documented recurrence of disease or new primary NSCLC as determined by the investigator, or death from any cause, whichever occurs first; \$Assessment by CT scan where MRI not available; NCT03456076








Figure 1. Disease-free Survival among Patients with Stage II or IIIA Disease and in the Intention-to-Treat Population.

The intention-to-treat population included patients with stage IB, II, or IIIA disease who had undergone randomization. Disease staging was based on the seventh edition of the *Cancer Staging Manual* of the American Joint Committee on Cancer and Union for International Cancer Control (AJCC–UICC). The widths of the confidence intervals (indicated by shaded areas) have not been adjusted for multiplicity and may not be used in place of hypothesis testing. Tick marks indicate censored data. NE denotes could not be estimated.







National NCCN Guidelines Version 7.2024 **NCCN Guidelines Index** Comprehensive **Table of Contents** NCCN Cancer Non-Small Cell Lung Cancer Discussion Network[®] PERIOPERATIVE SYSTEMIC THERAPY Systemic Therapy Following Surgical Resection^c • Test for PD-L1 status, EGFR mutations, and ALK rearrangements (stages IB-IIIA, IIIB [T3,N2]). Principles of Molecular and Biomarker Analysis (NSCL-H). • Alectinib 600 mg twice daily for 24 months¹² > For patients with completely resected stage II–IIIA or stage IIIB (T3, N2) NSCLC and positive for ALK rearrangements (category 1). Osimertinib 80 mg daily for 3 years → For patients with completely resected stage IB–IIIA or stage IIIB (T3, N2) NSCLC and positive for EGFR (exon 19 deletion, exon 21 L858R) mutations who received previous adjuvant chemotherapy or are ineligible to receive platinum-based chemotherapy. • Atezolizumab 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks for up to 1 year¹⁴ For patients with completely resected stage IIB–IIIA, stage IIIB (T3, N2), or high-risk stage IIA NSCLC with PD-L1 ≥1% and negative for EGFR exon 19 deletion or exon 21 L858R mutations or ALK rearrangements who received previous adjuvant chemotherapy and with no contraindications to immune checkpoint inhibitors.^a Pembrolizumab 200 mg every 3 weeks or 400 mg every 6 weeks for up to 1 year > For patients with completely resected stage IIB-IIIA, stage IIIB (T3, N2), or high-risk stage IIA NSCLC and negative for EGFR exon 19 deletion or exon 21 L858R mutations or ALK rearrangements who received previous adjuvant chemotherapy and with no contraindications to immune checkpoint inhibitors.^{a,15} The benefit for patients with PD-L1 <1% is unclear. > For patients with completely resected stage II-IIIA or stage IIIB (T3, N2) NSCLC who received previous neoadjuvant pembrolizumab + chemotherapy (category 1).²

Updates in Early Stage NSCLC: EGFR exon19/L858R



Osimertinib after definitive chemoradiotherapy in patients with unresectable stage III epidermal growth factor receptor-mutated (EGFRm) NSCLC: primary results of the Phase 3 LAURA study

<u>Suresh S. Ramalingam,</u>¹ Terufumi Kato, Xiaorong Dong, Myung-Ju Ahn, Le-Van Quang, Nopadol Soparattanapaisarn, Takako Inoue, Chih-Liang Wang, Meijuan Huang, James Chih-Hsin Yang, Manuel Cobo, Mustafa Özgüroğlu, Ignacio Casarini, Dang-Van Khiem, Virote Sriuranpong, Eduardo Cronemberger, Xiangning Huang, Toon van der Gronde, Dana Ghiorghiu, Shun Lu


¹Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA, USA





Updates in Early Stage NSCLC: EGFR exon19/L858R

LAURA Phase 3 double-blind study design



Endpoints

- Primary endpoint: PFS assessed by BICR per RECIST v1.1 (sensitivity analysis: PFS by investigator assessment)
- · Secondary endpoints included: OS, CNS PFS, safety



PRESENTED BY: Dr Suresh S. Ramalingam Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org

AJCC, American Joint Committee on Cancer; BICR, blinded independent central review; CLIA, Clinical Laboratory Improvement Amendments; CNS, central nervous system; CRT, otemoradio/herapy; CT, computed temography; EGFRm, ejdermal growth factor respectiventuation, Ex15del, exon 19 deteion; FDA, Fodo and Orug Administration; MRJ, Imagentic reasonare imaging; NSCL, on-small cell lung cancer; UICC, Union for International Cancer, ECHTO; WOOT Health Organization performance status




AMERICAN SOCIETY OF

^{*}According to AJCC / UICC staging (8th edition

^{*}Concurrent or sequential CRT comprising ≥2 cycles of platinum-based chemotherapy (or 5 doses of weekly platinum-based chemotherapy) and a total dose of radiation of 60 cy ±10%; +Central or FDA-approved local testing (from a CLIA-approved laboratory, or accredited local laboratory for sites outside of USA) based on tissue; + dentral or FDA-approved local testing (from a CLIA-approved laboratory, or accredited local laboratory for sites outside of USA) based on tissue; + dentral or FDA-approved local testing (from a CLIA-approved laboratory, or accredited local laboratory for sites outside of USA) based on tissue; + dentral or FDA-approved laboratory, or accredited incal benefit (osimethib arm); by the judgement of treating physician (placebo arm).

Updates in Early Stage NSCLC: EGFR exon19/L858R 🖤

Progression-free survival by BICR




KNOWLEDGE CONOUEDE CANCER

Presentation is property of the author and ASCO. Permission required for reuses contact permissions@acco org

Updates in Early Stage NSCLC: EGFR exon19/L858R

Progression-free survival by investigator assessment



2024 ASCC ANNUAL MEETING



PRESENTED BY: Dr Suresh S. Ramalingam



Updates in Early Stage NSCLC: EGFR exon19/L858R 🗍

Progression-free survival by BICR across subgroups

Subgroup		No. of events	/ patients					1		HR	95% CI
Overall (N=216)	Stratified log-rank	120	/ 216							0.16	0.10, 0.24
	Unadjusted Cox PH	120	/ 216		F					0.23	0.16, 0.33
Sex	Male	50	/ 84							0.26	0.15, 0.46
	Female	70	/ 132		F					0.21	0.13, 0.34
Age	<65 years	67	/ 120							0.16	0.10, 0.26
	≥65 years	53	/ 96							0.33	0.19, 0.57
Race	Asian	98	/ 178			-				0.20	0.13, 0.29
	Non-Asian	22	/ 38				-	-		0.48	0.20, 1.19
Smoking history	Current / former (yes)	42	/ 65							0.26	0.14, 0.48
	Never (no)	78	/ 151			-				0.22	0.14, 0.34
Stage*	IIIA	42	/ 76							0.28	0.15, 0.52
	IIIB / IIIC	78	/ 140							0.21	0.13, 0.33
EGFR mutation [†]	Ex19del	65	/ 117		I					0.17	0.10, 0.29
	L858R	55	/ 98			-				0.32	0.19, 0.56
China cohort	Chinese	18	/ 40		N)				NC	NC, NC
	Non-Chinese	102	/ 176							0.26	0.17, 0.39
Chemoradiotherapy	Concurrent	107	/ 193							0.25	0.17, 0.36
	Sequential	13	/ 23		NC					NC	NC, NC
Response to prior CRT	Complete response	3	/ 7		NC					NC	NC, NC
	Partial response	53	/ 94							0.20	0.11, 0.34
	Stable disease	58	/ 98							0.18	0.10, 0.30
	Non-evaluable	6	/ 17		NC					NC	NC, NC
				0.05		0).5	1.0	5		
				0.00				free survival (
						Favors os	imertinib	Favors plac	ebo		

Data cut-off January 5 2024

AMERICAN SOCIETY OF

Note: HRs were calculated only for subgroups with >20 events across both arms to allow for meaningful analysis. Subgroup (not prespecified) of WHO PS: PS=0 HR 0.17 (95% CI 0.10, 0.28); PS=1 HR 0.34 (95% CI 0.20, 0.56) *Stage prior to CRT by AICC / UICC staging (8th edition

'Central test of tumor tissue at screening, or local pre-existing test result; one patient in the osimertinib arm had missing EGFR mutation information

A ICC. American Joint Committee on Cancer: BICR, blinded independent central review; CI, confidence AJCC, American Joint Committee on Cancer, BICR, blinded independent central review, CI, confidence interval; CRT, chemoradiotherapy, EGFR, epidermal growth factor receptor; Ex19del, exon 19 deletion; ASCOC CLINICAL ONCOLOGY HR, hazard ratio; NC, not calculable; PFS, progression-free survival; PH, proportional-hazards model; KNOWLEDGE CONQUERS CANCER UICC, Union for International Cancer Control; WHO PS, World Health Organization performance status






#ASCO24 Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org

Updates in Early Stage NSCLC: EGFR exon19/L858R

Interim analysis of overall survival

In the placebo arm, 81% of patients with BICR-confirmed progression crossed over to osimertinib •




SCO AMERICAN SOCIETY C NR. not reached: OS. overall survival KNOWLEDGE CONQUERS CANCER

PRESENTED BY: Dr Suresh S. Ramalingam


ANNUAL MEETING

Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org

Updates in Early Stage NSCLC: EGFR exon19/L858R



Updates in Early Stage NSCLC: EGFR exon19/L858R 🔰





- ✓ Adjuvant Alectinib after surgery is a standard of care for Stage II-IIIB NSCLC after surgical resection.
- Consolidation Osimertinib is the new standard of care of for EGFR Exon 19/L858R after chemoradiation therapy.
- Neoadjuvant/perioperative immunotherapy remains the standard of care for ALK/EGFR non-mutated NSCLC. Clinical trials to improve pathological complete responses in this stage.





Lorlatinib vs Crizotinib in Treatment-Naive Patients With Advanced *ALK*+ Non-Small Cell Lung Cancer: 5-Year Progression-Free Survival and Safety From the CROWN Study

<u>Benjamin J. Solomon</u>,¹ Geoffrey Liu,² Enriqueta Felip,³ Tony S. K. Mok,⁴ Ross A. Soo,⁵ Julien Mazieres,⁶ Alice T. Shaw,⁷ Filippo de Marinis,⁸ Yasushi Goto,⁹ Yi-Long Wu,¹⁰ Dong-Wan Kim,¹¹ Jean-François Martini,¹² Rossella Messina,¹³ Jolanda Paolini,¹³ Anna Polli,¹³ Despina Thomaidou,¹⁴ Francesca Toffalorio,¹³ Todd M. Bauer¹⁵

¹Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; ²Princess Margaret Cancer Centre, Toronto, ON, Canada; ³Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain; ⁴State Key Laboratory of Translational Oncology, Chinese University of Hong Kong, Hong Kong; ⁵National University Cancer Institute, Singapore; ⁶Toulouse University Hospital and Centre de Recherche Cancérologie Toulouse CRCT, INSERM, France; ⁷Massachusetts General Hospital Cancer Center, Boston, MA, USA; ⁸European Institute of Oncology, IRCCS, Milan, Italy; ⁹National Cancer Center Hospital, Tokyo, Japan; ¹⁰Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangdong, China; ¹¹Seoul National University College of Medicine and Seoul National University Hospital, Seoul, South Korea; ¹²Pfizer, La Jolla, CA, USA; ¹³Pfizer, Milan, Italy; ¹⁴Pfizer, Athens, Greece; ¹⁵Greco-Hainsworth Centers for Research/Tennessee Oncology, Nashville, TN, USA

Benjamin J. Solomon, MBBS, PhD Peter MacCallum Cancer Centre, Melbourne, VIC, Australia








CROWN: A Randomized Global Phase 3 Study

• Lorlatinib is a brain-penetrant, third-generation ALK TKI that has broader coverage of ALK resistance mutations than second-generation ALK TKIs^{1,2}



- At the planned interim analysis, at 18.3 months of median follow-up in the lorlatinib arm, median PFS by BICR was not reached (95% CI, NR-NR) with lorlatinib and 9.3 months (95% CI, 7.6-11.1 months) with crizotinib, with an HR of 0.28 (95% CI, 0.19-0.41) and P<0.001³
- In a subsequent post hoc analysis, at 3 years of follow-up, median PFS by BICR was still not reached (95% CI, NR-NR) with lorlatinib and 9.3 months (95% CI, 7.6-11.1 months) with crizotinib (HR, 0.27; 95% CI, 0.18-0.39)⁴

ALK, anaplastic lymphoma kinase; BICR, blinded independent central review; CNS, central nervous system; DOR, duration of response; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; IC, intracranial; NR, not reached; NSCLC, non-small cell lung cancer; ORR, objective response rate; PFS, progression-free survival; PS, performance status; RECIST, Response Evaluation Criteria in Solid Tumors; TKI, tyrosine kinase inhibitor; TTP, time to tumor progression; TTR, time to tumor response. *Defined as the time from randomization to RECIST-defined progression or death due to any cause. 1. Johnson TW, et al. *J Med Chem.* 2014;57:4720-4744. 2. Shaw AT, et al. *Lancet Oncol.* 2017;18:1590-1599. 3. Shaw AT, et al. *N Engl J Med.* 2020;383:2018-2029. 4. Solomon BJ, et al. *Lancet Respir Med.* 2023;11:354-366.




PRESENTED BY: Benjamin J. Solomon (Ben.Solomon@petermac.org) Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org.





Current Post Hoc Analyses at 5 Years

Endpoint evaluation by BICR stopped after the 3-year analysis



 The median duration of follow-up for PFS was 60.2 months (95% CI, 57.4-61.6) in the lorlatinib arm and 55.1 months (95% CI, 36.8-62.5) in the crizotinib arm

CNS, central nervous system; DOR, duration of response; ECOG, Eastern Cooperative Oncology Group; IC, intracranial; ORR, objective response rate; NSCLC, non-small cell lung cancer; PFS, progression-free survival; PS, performance status; RECIST, Response Evaluation Criteria in Solid Tumors; TTP, time to tumor progression. ^a Defined as the time from randomization to RECIST-defined progression or death due to any cause.






PRESENTED BY: Benjamin J. Solomon (Ben.Solomon@petermac.org) Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org.



Updates in Late Stage NSCLC



At 60.2 Months of Median Follow-Up, Median PFS by Investigator Was Still Not Reached With Lorlatinib



HR, hazard ratio; NR, not reached; OS, overall survival; PFS, progression-free survival.




#ASCO24 PRESENTED BY: Benjamin J. Solomon (Ben.Solomon@petermac.org) Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org.






ALK REARRANGEMENTⁿⁿ




Updates in Late Stage NSCLC: KRAS G12C

KRYSTAL-12: ADA in previously treated KRASG12C NSCLO

KRYSTAL-12^a study design



Primary endpoint: PFS^a per BICR



Database lock: March 19, 2024. Data cut-off: December 31, 2023.


*NCT04685135. ^bDetected in tumor tissue using sponsor-approved local or central testing. No washout period was required between prior therapy and study treatment. ^dTablet formulation, except for four patients who initially received the capsule formulation. ^sOther crossover criteria: ECOG PS 0-2, recovery from DOCE-related AEs to grade 1 or baseline (except peripheral neuropathy and alopecia for which grade 2 is acceptable).

Median follow-up: 7.2 months.

^aTime from randomization to the date of disease progression per BICR or death due to any cause, whichever occurs first. For patients who started a subsequent anticancer therapy prior to disease progression or death, PFS was censored at the date of the last tumor assessment prior to the start of the new therapy.



Intracranial response per BICR^a




^aIn accordance with CNS-adapted RECIST v1.1. CNS RECIST data (including identification of patients with baseline CNS metastases) were based on a separate CNS imaging charter and neuroradiologist review. ^bWaterfall plots show CNS evaluable population including patients with at least one CNS target lesion at baseline and at least one post-baseline CNS tumor assessment. For lesions to be considered target lesions, they must have been measurable and either not previously treated with CNS-directed therapy or must have progressed after prior CNS-directed therapy.

Updates in Late Stage NSCLC: KRAS G12C



SUNRAY-01 is a pivotal, global, phase 3 study in 1L advanced KRAS G12C-mutated NSCLC (NCT06119581)



- Olomorasib/placebo are administered orally, twice daily
- Pembrolizumab, pemetrexed, and platinum (cisplatin or carboplatin) are each administered intravenously per label. After completing 4 cycles of chemotherapy without disease progression, patients will receive maintenance therapy with olomorasib/placebo, pembrolizumab and pemetrexed

^aParticipants should be suitable for pembrolizumab monotherapy

^bPD-L1 expression 0-100%, N~40 for each study part (randomized Dose Optimization and Safety Lead-In Part B) ^cParticipants with PD-L1 ≥50% are eligible to be enrolled to Part A or Part B at the discretion of the investigator

Negrao at al, Asco 2024

Updates in Late Stage NSCLC: HER2






Phase Ia/Ib trial of zongertinib (BI 1810631), a HER2-specific tyrosine kinase inhibitor in patients with HER2 aberration-positive solid tumors: updated Phase Ia data from Beamion LUNG-1, including progression-free survival data

John Heymach,¹ Frans Opdam,² Minal Barve,³ Hai-Yan Tu,⁴ Yi-Long Wu,⁴ David Berz,⁵ Maren Rohrbacher,⁶ Behbood Sadrolhefazi,⁷ Josep Serra,⁸ Kiyotaka Yoh,⁹ Noboru Yamamoto¹⁰

1. Department of Thoracic-Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA; 2. Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; 3. Mary Crowley Cancer Research, Dallas, TX, USA; 4. Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China; 5. Valkyrie Clinical Trials, Inc., Los Angeles, CA, USA; 6. Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany; 7. Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA; 8. Boehringer Ingelheim España S.A., Barcelona, Spain; ⁹Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan; ¹⁰Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan

Updates in Late Stage NSCLC: HER2






Updates in Late Stage NSCLC: HER2



#TPS8654

Beamion LUNG-2: a Phase III randomized controlled trial of zongertinib (BI 1810631) versus standard of care in patients with locally advanced/metastatic non-squamous non-small cell lung cancer (NSCLC) harboring *HER2* tyrosine kinase domain (TKD) mutations



• Treatment across both arms will continue until documented progressive disease (RECIST v1.1, according to independent central review), undue toxicity, withdrawal of consent or other defined criteria are met

*Intravenous 500 mg/m² pemetrexed chemotherapy plus 200 mg intravenous pembrolizumab followed by either 75 mg/m² cisplatin or carboplatin Area Under the Curve 5 on Day 1 (determined by investigator prior to randomization), every three weeks, for four 21-day treatment cycles, followed by maintenance therapy with 200 mg pembrolizumab plus pemetrexed 500 mg/m² every three weeks for up to 35 cycles



Presented at the American Society of Clinical Oncology (ASCO), Chicago, IL, USA, May 31–June 4, 2024 *Corresponding author email address: melissa.johnson@scri.com



- ✓ Lorlatinib remains one standard of care option for Stage IV ALK+ NSCLC.
- ✓ Adagrasib remains one standard of care for Stage IV KRAS G12C NSCLC.
- New KRAS targeted molecules in clinical development, being tested alone and in combination with immunotherapy and chemotherapy.
- ✓ Zongertinib is a promising HER2 targeted therapy.

Acknowledgements



- Lung Cancer Initiative
- Summit Organizers
- Patients and their families
- Duke thoracic oncology program

